Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis最新文献

{"title":"Establishment Trimester-Specific Reference Intervals of Anticoagulation and Fibrinolysis Indicators in Healthy Pregnant Women in Beijing, China.","authors":"Linzi Miao, Xiao Sun, Zijing Zhu, Yuanyuan Li, Yao Lu, Ran You, Chenxue Qu","doi":"10.1177/10760296251342456","DOIUrl":"10.1177/10760296251342456","url":null,"abstract":"<p><p>ObjectiveContinuously tracking and monitoring the changes in indicators of anticoagulation and fibrinolysis in healthy pregnant women during different pregnancy periods, to establish trimester-specific reference intervals.MethodsA total of 200 healthy pregnant women registered in Peking University First Hospital were enrolled. Venous blood samples were collected at different pregnancy periods, and thirteen related anticoagulation and fibrinolysis indicators were tested. The impact of pregnancy periods on these indicators were analyzed, and corresponding reference intervals were established.ResultsSignificant differences were observed among the non-pregnant group and the first trimester(6-8weeks), second trimester(24-28weeks), and third trimester(36-38weeks) groups for antithrombin (AT), protein S activity (PS Ac), free protein S (FPS), protein C (PC), D-Dimer, fibrin/fibrinogen degradation products (FDP), plasmin inhibitor (PI), plasminogen (PLG), von Willebrand factor activity (vWF:Ac), von Willebrand factor antigen (vWF:Ag), lupus anticoagulant. AT, PS Ac, and FPS showed a downward trend with increasing gestational period. PI was significantly increased in the first trimester. PLG and vWF:Ag was higher in the second trimester and the third trimester. vWF:Ac, D-Dimer and FDP showed an continuously upward trend with increasing gestational period; the normalized SCT ratio (SCT TR)was significantly lower in the third trimester; the normalized dRVVT ratio (dRVVT TR)was significantly higher in the second and third trimester.ConclusionThis study established reference intervals for thirteen anticoagulant and fibrinolytic indicators in healthy pregnant women in Beijing, China. Additionally, pregnancy periods affect the test results of anticoagulant and fibrinolytic indicators in pregnant women, and the reference intervals should be established separately according to pregnancy periods.</p>","PeriodicalId":520590,"journal":{"name":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","volume":"31 ","pages":"10760296251342456"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists' Knowledge of Abnormal Uterine Bleeding in Women on Anticoagulant Therapy: A French Survey.","authors":"Sibylle Frerebeau, Benjamin Planquette, Gabrielle Sarlon, Nicolas Gendron","doi":"10.1177/10760296251350078","DOIUrl":"10.1177/10760296251350078","url":null,"abstract":"<p><p>ObjectivesThis study aimed to assess the role of community pharmacists in managing abnormal uterine bleeding (AUB) in women on anticoagulant therapy, particularly in the context of a physician shortage in France, which exacerbates the pharmacist's role. Recognizing these bleedings, which impair the quality of life for women, is an essential role of pharmacists and could be crucial in preventing the risk of discontinuing anticoagulant treatment.MethodsWe conducted an anonymous survey from December 2023 to January 2024 among pharmacists in France to explore their experiences with patients on anticoagulants who presented at pharmacies with questions about AUB.ResultsOf the 115 respondents, only 9 (7.8%) pharmacists had been approached by patients with questions about AUB while on anticoagulants. These pharmacists reported a majority of cases in women of reproductive age, the drug the most frequently cited was rivaroxaban. No significant demographic differences were observed between the pharmacists who had faced these questions and those who had not. Additionally, 99 (86.1%) pharmacists considered that they did not have enough skills to adequately advise female patients about abnormal uterine/genital bleeding under anticoagulant therapy.ConclusionOur study showed that community pharmacists are not the primary healthcare contact for patients with AUB under anticoagulant therapy. Despite this, the low frequency of pharmacist-patient interactions regarding AUB suggests potential under-diagnosis and under-communication of adverse effects that negatively impact the quality of life of women on anticoagulants.</p>","PeriodicalId":520590,"journal":{"name":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","volume":"31 ","pages":"10760296251350078"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linking Cortical Structure and Cerebrospinal Fluid Metabolites with Venous Thromboembolism Risk: A Two-Step Mendelian Randomization and Co-Localization Analysis.","authors":"Tianni Liu, Junxian Li, Qiong Liu, Guojun Liang","doi":"10.1177/10760296251360018","DOIUrl":"10.1177/10760296251360018","url":null,"abstract":"<p><p>BackgroundVenous thromboembolism (VTE) is a complex vascular disorder, and emerging research suggests potential neurovascular and metabolic factors in its pathogenesis. However, the specific roles of cortical structure features and cerebrospinal fluid (CSF) metabolites in VTE risk remain underexplored.MethodsUsing Mendelian randomization (MR) analysis, we examined associations between cortical features, CSF metabolites and VTE. Mediation MR and co-localization analyses were employed to explore genetic pathways and potential mediatory effects.ResultsMR analysis initially identified associations between six cortical features and fifteen CSF metabolites with VTE. After false discovery rate (FDR) correction, lingual gyrus thickness remained statistically significant, while isoleucine and methylmalonate showed suggestive associations. Mediation MR analysis revealed no causal relationship between lingual gyrus thickness and the CSF metabolites isoleucine or methylmalonate. Co-localization analysis indicated low posterior probabilities for shared genetic variants, suggesting that these traits influence venous thromboembolism (VTE) through distinct biological mechanisms.ConclusionThe findings suggest that MRI-based cortical structure features and CSF profiling hold potential as complementary tools for assessing VTE risk. Further research is warranted to investigate the neurovascular and metabolic mechanisms underlying VTE.</p>","PeriodicalId":520590,"journal":{"name":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","volume":"31 ","pages":"10760296251360018"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of Two Potential Predictors of Thrombosis Risk in Polycythemia Vera: Hematocrit-to-Hemoglobin Ratio and HALP Score.","authors":"Deniz Yilmaz, Eyyup Akkaya","doi":"10.1177/10760296251347630","DOIUrl":"10.1177/10760296251347630","url":null,"abstract":"<p><p><b>Objective:</b> This study aimed to assess the utility of the hematocrit-to-hemoglobin ratio (HHR) and the HALP score in detecting thrombosis history in patients with polycythemia vera (PV). <b>Methods:</b> This retrospective study examined patients diagnosed with PV between January 2013 and December 2022. Demographics, clinical history, PV- and thrombosis-related data, laboratory findings, follow-up duration, and mortality status were retrieved from hospital records. HHR and HALP scores were calculated for all patients. Patients were grouped based on their thrombosis history. <b>Results:</b> A total of 124 PV patients were included, with a mean age of 57.65 ± 12.17 years, and 86 (69.35%) were males. Thrombosis was present in 59 patients (47.58%), with 32.20% occurring before diagnosis, 23.73% at diagnosis, and 44.07% after diagnosis. Patients with and without thrombosis history were similar in age and sex. Those with a history of thrombosis had significantly higher anticoagulant use and HHR values, while other variables, including HALP score, showed no differences. An HHR cut-off value of >3.05 predicted thrombosis history with 54.24% sensitivity and 72.31% specificity. <b>Conclusion:</b> HHR could help distinguish PV patients with thrombosis history, though its sensitivity is low. HALP score was not associated with thrombosis risk.</p>","PeriodicalId":520590,"journal":{"name":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","volume":"31 ","pages":"10760296251347630"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144201348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Prothrombin complex Concentrate in Patients with Massive Intraoperative Bleeding During non-Cardiac Surgery: A Retrospective Cohort Study.","authors":"Bo Tang, Yuelun Zhang, Jia Gan, Lulu Ma, Yuguang Huang","doi":"10.1177/10760296251356202","DOIUrl":"10.1177/10760296251356202","url":null,"abstract":"<p><p>PurposeThe efficacy and safety of four-factor prothrombin complex concentrate (4F-PCC) in managing bleeding during non-cardiac surgery are unclear. We investigated the associations of 4F-PCC with postoperative RBC transfusion and adverse events in non-cardiac surgery patients with massive intraoperative bleeding.MethodsThis retrospective cohort study consecutively included non-cardiac surgery patients with massive intraoperative bleeding at a tertiary hospital (2014-2020). Administration of 4F-PCC was categorized into dose groups based on quartiles: 0 (reference), 2.8-6.7, 6.7-11.5, 11.5-19.4, and 19.4-87.5 IU/kg. Outcomes included postoperative RBC transfusion, major thromboembolic events, severe acute kidney injury, and lengths of ICU and hospital stay.ResultsOf 137 patients, 89 (65.0%) received 4F-PCC. The 6.7-11.5 IU/kg group were significantly associated with reduced postoperative RBC transfusion compared to the non-4F-PCC group (adjusted mean difference, -1.29 units; 95%CI, -2.55 to -0.04 units, <i>P</i> = 0.044). Such findings were not observed in other dose groups. Notably, the benefits were particularly significant in patients with preoperative platelet count ≥150 × 109/l (<i>P</i> = 0.031), and fibrinogen ≥3 g/l (<i>P</i> = 0.025). The 6.7-11.5 IU/kg group exhibited comparable incidences of major thromboembolic events (13.0% vs 10.4%) and severe acute kidney injury (8.7% vs 8.3%) compared to the non-4F-PCC group. The lengths of ICU and hospital stay were similar across groups.Conclusion4F-PCC may be associated with decreased postoperative RBC transfusion in non-cardiac surgery patients experiencing massive intraoperative bleeding, without a significant increase in the risk of major thromboembolic events. Randomized trials with stratified dosing are warranted to confirm efficacy, safety, and determine optimal doses.Clinical Trial NumberChiCTR2500096573.</p>","PeriodicalId":520590,"journal":{"name":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","volume":"31 ","pages":"10760296251356202"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coagulation and Fibrinolysis Dysregulation in β-Thalassemia Major: Potential Impact of Splenectomy and Medications on Thrombotic Risk.","authors":"Ola M Al-Sanabra, Manal A Abbas, Wafà J Hazà, Abeer A Hazàa, Ahmad K Al Tibi","doi":"10.1177/10760296251359291","DOIUrl":"10.1177/10760296251359291","url":null,"abstract":"<p><p>ObjectiveThe dysregulation of clotting factors in β-thalassemia major is not fully understood. This case-control study examines the impact of splenectomy and medications on clotting factor dysregulation.MethodsLab. tests of coagulation and fibrinolysis were performed.ResultsThis study included 60 β-thalassemia major patients of both sexes (7-35 years) and 20 age-matched controls. None of the participants had a previous thrombotic event. No difference existed between control and β-thalassemia groups in all tested parameters except for protein S (PS) which was 26.1% lower in β-thalassemia group compared to the control group (p = 0.0001) while D-Dimer, plasminogen activator inhibitor-1 (PAI-1) and platelet count showed an increase in their levels by 53.6%, 93.4% and 112.7%, respectively compared to the control (p = 0.004, p = 0.0001, p = 0.0001, respectively). Notably, a strong positive correlation existed between platelet count and PAI-1 (r = 0.669, p = 0.0001) in β-thalassemia group. Splenectomized patients had higher platelet count (+45.2%), PAI-1 (+98.1%), fibrinogen (+18.9%) and tPA (+197.2%) compared to the non-splenectomized group (all p < 0.05). No significant differences in PS, D-dimer, PT, INR, aPTT, fibrinogen, PC, TF, tPA or ADAMTS13 were found between β-thalassemia major patients taking and not taking aspirin. However, a higher platelet count (+37.1%) and PAI-1 level (+58.9%), along with a lower vWF level (-25.6%), were observed between these two groups (all p < 0.05).ConclusionElevation in PAI-1 and platelet count in splenectomized β-thalassemia major could increase the risk of having a thrombotic event. Medications may have significant interactions with blood coagulation in β-thalassemia.</p>","PeriodicalId":520590,"journal":{"name":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","volume":"31 ","pages":"10760296251359291"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thanks to Reviewers.","authors":"","doi":"10.1177/10760296221077326","DOIUrl":"10.1177/10760296221077326","url":null,"abstract":"","PeriodicalId":520590,"journal":{"name":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","volume":"31 ","pages":"10760296221077326"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study on Cerebral Venous Thrombosis From 2014 to 2023: A Bibliometric Analysis via CiteSpace.","authors":"Min Li, Shuling Wan, Xuefan Yao, Ran Meng, Xunming Ji","doi":"10.1177/10760296251359289","DOIUrl":"10.1177/10760296251359289","url":null,"abstract":"<p><p>ObjectiveWe aimed to explore the development status, turning and key points, and emerging trends of the cerebral venous thrombosis (CVT).MethodsLiterature pertaining to CVT published from 2014 to 2023 in the Web of Science Core Collection database was searched. The 6.3.R1 version of CiteSpace software was used to conduct a bibliometric analysis.ResultsA total of 2421 articles were ultimately retained. The annual publication volume exhibited a general trend of gradual growth, culminating in 2022. In terms of both publication volume and citation frequency, the journal \"Stroke\" emerges as the preeminent publication with high quantity and quality. The United States, China and India have become the foremost contributors while Pakistan and England exhibit a strong international collaboration. Ferro JM from Universidade de Lisboa, Coutinho JM from University of Amsterdam and Ji XM from Capital Medical University from are identified as the leading scholars. Burst analyses of keyword and co-cited references reveal that prior to 2021, the predominant research topics in the field of CVT were epidemiology, diagnosis and management, with increased attention to endovascular therapies and novel imaging modalities. From 2021 to 2023, the focus has shifted primarily to COVID-19 and vaccine-induced immune thrombotic thrombocytopenia (VITT).ConclusionOver the past decade, research on CVT has demonstrated continuous growth. The most influential institutions and scholars were from Europe and China. Our analysis showed that core research priorities in CVT centered on epidemiology, diagnosis and management while the COVID-19 pandemic temporarily shifted focus toward COVID-19 and VITT associated CVT.</p>","PeriodicalId":520590,"journal":{"name":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","volume":"31 ","pages":"10760296251359289"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144629300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment and Application of Warning Scoring System for Bleeding Severity in Patients with Newly Diagnosed Acute Promyelocytic Leukemia.","authors":"Xueqin Li, Hongying Tang, Yu Lian, Wei Liu, Xinyao Liu, Xinlei Yang, Yukai Jing","doi":"10.1177/10760296251360019","DOIUrl":"10.1177/10760296251360019","url":null,"abstract":"<p><p>Create and evaluate a scoring system to detect early moderate/severe bleeding in acute promyelocytic leukemia (APL).MethodsThe study used 89 APL patients from Shanxi Bethune Hospital (2014/01-2024/10) for development and 48 APL patients from Tianjin Medical University General Hospital (2021/08-2024/08) for validation. Logistic regression was used to analyze independent risk factors and develop a scoring system based on odds ratios, with ROC curves assessing the AUC. Both sets were classified into low and high risk using the system's cut-off, and the incidence of moderate/severe bleeding in each group was calculated. The scoring system's relationship with the ISTH DIC score and their combined diagnostic efficacy for DIC and bleeding events in APL patients were evaluated using AUC, specificity, and sensitivity.ResultsIn the development cohort, 15.7% (14 cases) had moderate/severe bleeding, while the validation cohort had 14.6% (7 cases). Multivariate logistic regression identified LDH levels ≥538 IU/L, fibrinogen <0.95 g/L, and D-Dimer ≥6865 ng/mL as independent risk factors for early moderate/severe bleeding in APL patients. The new warning scoring system had an AUC of 0.899 in the development group and 0.937 in the validation group. High-risk patients in both cohorts were significantly more likely to experience moderate/severe bleeding than low-risk patients (p < .001). The ISTH DIC score is significantly linked to both bleeding severity and the warning scoring system.ConclusionsThe warning scoring system shows potential for predicting the risk of moderate/severe bleeding in APL patients; however, further prospective validation studies are necessary to substantiate its efficacy.</p>","PeriodicalId":520590,"journal":{"name":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","volume":"31 ","pages":"10760296251360019"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144652028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LncRNA NEXN-AS1 Serves as a Diagnostic Biomarker for Carotid Artery Stenosis, Forecasting Cerebral Ischemic Events.","authors":"Weilong Liu, Dandan Jia, Lijun Yang, Zhenzeng Fan","doi":"10.1177/10760296251361084","DOIUrl":"10.1177/10760296251361084","url":null,"abstract":"<p><p>ObjectiveCarotid artery stenosis (CAS) is a significant contributor to cerebral ischemic events (CIEs). This study investigated the expression pattern and clinical significance of lncRNA NEXN-AS1 in CAS and CIEs.Methods132 patients with CAS and 98 controls were enrolled. RT-qPCR was employed to quantify serum levels of NEXN-AS1 and miR-92a-1-5p. The diagnostic utility of NEXN-AS1 for CAS was assessed using ROC curves. Logistic regression pinpointed potential risk factors for severe CAS. Patients were followed for 2 years, and Kaplan-Meier and Cox methods evaluated the prognostic role of NEXN-AS1 and risk factors for CIEs in CAS cases. RIP and DLR assays were conducted to confirm the association between NEXN-AS1 and miR-92a-1-5p.ResultsSerum NEXN-AS1 was less expressed in CAS patients than in controls, which could effectively distinguish between the two groups with high sensitivity and specificity. CAS patients with severe stenosis had lower serum NEXN-AS1 levels than those with moderate stenosis. Patients with low NEXN-AS1 expression were more prone to developing CIEs compared to those with high expression (log-rank P = .0051). Cox regression analysis identified NEXN-AS1 as an independent risk factor for the development of CIEs. Molecularly, the target of NEXN-AS1 is miR-92a-1-5p.ConclusionPatients with low NEXN-AS1 expression could serve as diagnostic indicators for CAS and may predict the occurrence of CIEs. This study may offer new insights into the management of CAS and CIEs.</p>","PeriodicalId":520590,"journal":{"name":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","volume":"31 ","pages":"10760296251361084"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144684023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}